The CRC Blueprint

My scientific approach to my own cancer – shared with you.

Phase 2

Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon Cancer

Phase 2 · randomised · 353 people · 6 sites in Netherlands · Recruiting now

August 7, 2026
TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Phase 2 · randomised · 110 people · 3 sites in 2 countries · Recruiting now

August 7, 2026
Evaluation of RBS2418 in Patients With Advanced, Metastatic, and Progressive Colorectal Cancer

Phase 2 · randomised · 150 people · 5 sites in 3 countries · Recruiting now

August 7, 2026
A Study of Neoadjuvant Dostarlimab Plus Capecitabine Plus Oxaliplatin (CAPEOX) Vs CAPEOX With Previously Untreated T4N0 or Stage III Mismatch Repair Proficient (MMRp)/Microsatellite Stable (MSS) Colon Cancer

Phase 2 · randomised · 120 people · 33 sites in 6 countries · Recruiting now

August 7, 2026
A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers

Phase 2 · 220 people · 55 sites in 13 countries · Recruiting now

August 7, 2026
A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

Phase 2 · randomised · 1,109 people · 47 sites in 8 countries · Recruiting now

August 7, 2026
A Clinical Study of Arfolitixorin in Patients With mCRC

Phase 2 · randomised · 90 people · 3 sites in Germany · Recruiting now

August 7, 2026
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation

Phase 2 · randomised · 86 people · 286 sites in 2 countries · Running, not taking new patients

August 7, 2026
Capecitabine/Oxaliplatin Chemotherapy and Cemiplimab With or Without Fianlimab or REGN7075 in Locally Advanced Rectal Cancer

Phase 2 · randomised · 66 people · 1 site in United States · Recruiting now

August 7, 2026
Phase I/II Study of the Combination Immunotherapy Regimen: SX-682, TriAdeno Vaccine, Retifanlimab and IL-15 Agonist N-803 (STAR15) for Metastatic Colorectal Cancer (mCRC)

Phase 2 · 60 people · 1 site in United States · Recruiting now

August 7, 2026